Specific targeting of CD33+ leukemia cells by a natural killer cell line modified with a chimeric receptor

Leukemia Research

Volumn 29, Issue 3, 2005, Pages 301-306

  Schirrmann, Thomas ^a   Pecher, Gabriele ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CD33; Chimeric receptor; Gene transfer; Leukemia; NK cells; Targeting

Indexed keywords

ARTICLE; CHIMERA; CONTROLLED STUDY; CYTOLYSIS; DNA MODIFICATION; EFFECTOR CELL; ELECTROPORATION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOID LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL LINE; CYTOTOXICITY TESTS, IMMUNOLOGIC; ELECTROPORATION; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; LEUKEMIA; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 12344276425     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.07.005     Document Type: Article

References (27)

1. Z. Eshhar Tumor-specific T-bodies: towards clinical application Cancer Immunol. Immunother. 45 1997 131 136
2. M. Whitlow, B.A. Bell, S.L. Feng, D. Filpula, K.D. Hardman, and S.L. Hubert An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability Protein Eng. 6 1993 989 995
3. S.R. Riddell, M. Elliott, D.A. Lewinsohn, M.J. Gilbert, L. Wilson, and S.A. Manley T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients Nat. Med. 2 1996 216 223
4. R.P. McGuinness, Y. Ge, S.D. Patel, S.V. Kashmiri, H.S. Lee, and P.H. Hand Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor Hum. Gene Ther. 10 1999 165 173
5. A. Hombach, J.M. Muche, M. Gerken, S. Gellrich, C. Heuser, and C. Pohl T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells Gene Ther. 8 2001 891 895
6. T.L. Whiteside, M.W. Sung, S. Nagashima, K. Chikamatsu, K. Okada, and N.L. Vujanovic Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo Clin. Cancer Res. 4 1998 1135 1145
7. L. Ruggeri, M. Capanni, M.F. Martelli, and A. Velardi Cellular therapy: exploiting NK cell alloreactivity in transplantation Curr. Opin. Hematol. 8 2001 355 359
8. S. Visonneau, A. Cesano, D.L. Porter, S.L. Luger, L. Schuchter, and M. Kamoun Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer Clin. Cancer Res. 6 2000 1744 1754
9. T. Tonn, S. Becker, R. Esser, D. Schwabe, and E. Seifried Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92 J. Hematother. Stem Cell Res. 10 2001 535 544
10. A.C. Tran, D. Zhang, R. Byrn, and M.R. Roberts Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes J. Immunol. 155 1995 1000 1009
11. T. Schirrmann, and G. Pecher Tumor-specific targeting of a cell line with natural killer cell activity by asialoglycoprotein receptor gene transfer Cancer Immunol. Immunother. 50 2001 549 556
12. C. Uherek, T. Tonn, B. Uherek, S. Becker, B. Schnierle, and H.G. Klingemann Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction Blood 100 2002 1265 1273
13. J. Yodoi, K. Teshigawara, T. Nikaido, K. Fukui, T. Noma, and T. Honjo TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J. Immunol. 134 1985 1623 1630
14. P.C. Caron, and D.A. Scheinberg Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia Leuk. Lymphoma 11 Suppl 2 1993 1 6
15. T. Schirrmann, and G. Pecher Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo Cancer Gene Ther. 9 2002 390 398
16. W. Uckert, G. Willimsky, F.S. Pedersen, T. Blankenstein, and L. Pedersen RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes Hum. Gene Ther. 9 1998 2619 2627
17. M.E. Weijtens, R.A. Willemsen, E.H. Hart, and R.L. Bolhuis A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes Gene Ther. 5 1998 1195 1203
18. C. Bordignon, C. Carlo-Stella, M.P. Colombo, A. De Vincentiis, L. Lanata, and R.M. Lemoli Cell therapy: achievements and perspectives Haematologica 84 1999 1110 1149
19. M.R. Bochan, W.S. Goebel, and Z. Brahmi Stably transfected antisense granzyme B and perforin constructs inhibit human granule-mediated lytic ability Cell Immunol. 164 1995 234 239
20. A.H. Montel, M.R. Bochan, W.S. Goebel, and Z. Brahmi Fas-mediated cytotoxicity remains intact in perforin and granzyme B antisense transfectants of a human NK-like cell line Cell Immunol. 165 1995 312 317
21. S. Hacein-Bey-Abina, C. Von Kalle, M. Schmidt, M.P. McCormack, N. Wulffraat, and P. Leboulch LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 Science 302 2003 415 419
22. P.C. Caron, L. Dumont, and D.A. Scheinberg Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia Clin. Cancer Res. 4 1998 1421 1428
23. S.E. Kossman, D.A. Scheinberg, J.G. Jurcic, J. Jimenez, and P.C. Caron A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia Clin. Cancer Res. 5 1999 2748 2755
24. C. Vitale, C. Romagnani, M. Falco, M. Ponte, M. Vitale, and A. Moretta Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells Proc. Natl. Acad. Sci. USA 96 1999 15091 15096
25. M.C. Mingari, C. Vitale, C. Romagnani, M. Falco, and L. Moretta p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells Immunol. Rev. 181 2001 260 268
26. C. Vitale, C. Romagnani, A. Puccetti, D. Olive, R. Costello, and L. Chiossone Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells Proc. Natl. Acad. Sci. USA 98 2001 5764 5769
27. H.G. Klingemann, E. Wong, and G. Maki A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood Biol. Blood Marrow Transplant. 2 1996 68 75